Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Current Leases (2019 - 2021)

Cyclerion Therapeutics has reported Current Leases over the past 3 years, most recently at $1.4 million for Q1 2021.

  • Quarterly results put Current Leases at $1.4 million for Q1 2021, down 47.53% from a year ago — trailing twelve months through Mar 2021 was $1.4 million (down 47.53% YoY), and the annual figure for FY2020 was $3.3 million, down 3.71%.
  • Current Leases for Q1 2021 was $1.4 million at Cyclerion Therapeutics, down from $3.3 million in the prior quarter.
  • Over the last five years, Current Leases for CYCN hit a ceiling of $3.4 million in Q4 2019 and a floor of $866000.0 in Q2 2019.
  • Median Current Leases over the past 3 years was $3.0 million (2020), compared with a mean of $2.6 million.
  • Biggest five-year swings in Current Leases: soared 221.82% in 2020 and later plummeted 47.53% in 2021.
  • Cyclerion Therapeutics' Current Leases stood at $3.4 million in 2019, then fell by 3.71% to $3.3 million in 2020, then crashed by 57.49% to $1.4 million in 2021.
  • The last three reported values for Current Leases were $1.4 million (Q1 2021), $3.3 million (Q4 2020), and $3.1 million (Q3 2020) per Business Quant data.